Structure Therapeutics (GPCR) Total Current Liabilities (2022 - 2026)

Structure Therapeutics' Total Current Liabilities history runs 5 years deep, the most recent figure standing at $57.0 million for Q1 2026.

• On a quarterly basis, Total Current Liabilities rose 56.18% year-over-year to $57.0 million in Q1 2026; TTM through Mar 2026 was $57.0 million, a 56.18% increase from a year earlier, with the FY2025 full-year figure at $63.3 million, up 75.69% from the prior year.
• Total Current Liabilities slipped to $57.0 million in Q1 2026 per GPCR's latest filing, from $63.3 million in the prior quarter.
• Across five years, Total Current Liabilities topped out at $63.3 million in Q4 2025 and bottomed at $11.0 million in Q1 2023.
• The 5-year median for Total Current Liabilities is $29.1 million (2023), against an average of $32.3 million.
• Biggest YoY gain for Total Current Liabilities was 114.38% in 2024; the steepest drop was 45.6% in 2024.
• Year by year, Total Current Liabilities stood at $13.0 million in 2022, then surged by 90.16% to $24.7 million in 2023, then jumped by 45.6% to $36.0 million in 2024, then soared by 75.69% to $63.3 million in 2025, then fell by 9.96% to $57.0 million in 2026.
• Per Business Quant, the three latest GPCR Total Current Liabilities figures stand at $57.0 million (Q1 2026), $63.3 million (Q4 2025), and $57.5 million (Q3 2025).